WO2004091630A8 - 眼に適用する疾患治療剤 - Google Patents
眼に適用する疾患治療剤Info
- Publication number
- WO2004091630A8 WO2004091630A8 PCT/JP2004/005479 JP2004005479W WO2004091630A8 WO 2004091630 A8 WO2004091630 A8 WO 2004091630A8 JP 2004005479 W JP2004005479 W JP 2004005479W WO 2004091630 A8 WO2004091630 A8 WO 2004091630A8
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- eye
- remedies
- estrogen
- diseases
- serm
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/26—Androgens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/34—Gestagens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Abstract
Priority Applications (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AT04727990T ATE488240T1 (de) | 2003-04-18 | 2004-04-16 | Mittel zur behanldung von krankheiten zur aufbringung auf das auge |
DE602004030103T DE602004030103D1 (de) | 2003-04-18 | 2004-04-16 | Mittel zur behanldung von krankheiten zur aufbringung auf das auge |
EP04727990A EP1621199B8 (en) | 2003-04-18 | 2004-04-16 | Remedies for diseases to be applied to eye |
AU2004229291A AU2004229291A1 (en) | 2003-04-18 | 2004-04-16 | Remedies for diseases to be applied to eye |
JP2005505476A JP4564920B2 (ja) | 2003-04-18 | 2004-04-16 | 眼に適用する疾患治療剤 |
CA002527175A CA2527175A1 (en) | 2003-04-18 | 2004-04-16 | Remedies for diseases to be applied to eye |
US11/252,013 US20060111318A1 (en) | 2003-04-18 | 2005-10-18 | Agent for treating eye diseases |
US13/039,147 US20110223269A1 (en) | 2003-04-18 | 2011-03-02 | Agent for treating eye diseases |
US13/039,140 US20110212200A1 (en) | 2003-04-18 | 2011-03-02 | Agent for treating eye diseases |
US13/039,127 US20110212199A1 (en) | 2003-04-18 | 2011-03-02 | Agent for treating eye diseases |
Applications Claiming Priority (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003114969 | 2003-04-18 | ||
JP2003-114969 | 2003-04-18 | ||
JP2003-132910 | 2003-05-12 | ||
JP2003132910 | 2003-05-12 | ||
JP2003329165 | 2003-09-19 | ||
JP2003-329165 | 2003-09-19 | ||
JP2003354135 | 2003-10-14 | ||
JP2003-354135 | 2003-10-14 | ||
PCT/JP2004/004709 WO2004093882A1 (ja) | 2003-04-18 | 2004-03-31 | 眼に適用する疾患治療剤 |
JPPCT/JP04/004709 | 2004-03-31 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/252,013 Continuation-In-Part US20060111318A1 (en) | 2003-04-18 | 2005-10-18 | Agent for treating eye diseases |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2004091630A1 WO2004091630A1 (ja) | 2004-10-28 |
WO2004091630A8 true WO2004091630A8 (ja) | 2005-11-24 |
Family
ID=33304160
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2004/005479 WO2004091630A1 (ja) | 2003-04-18 | 2004-04-16 | 眼に適用する疾患治療剤 |
Country Status (7)
Country | Link |
---|---|
EP (6) | EP1621199B8 (ja) |
JP (2) | JP4564920B2 (ja) |
AT (1) | ATE488240T1 (ja) |
AU (1) | AU2004229291A1 (ja) |
CA (1) | CA2527175A1 (ja) |
DE (1) | DE602004030103D1 (ja) |
WO (1) | WO2004091630A1 (ja) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2004229291A1 (en) * | 2003-04-18 | 2004-10-28 | Advanced Medicine Research Institute | Remedies for diseases to be applied to eye |
MX2007010359A (es) * | 2005-02-24 | 2008-04-04 | Diffusion Pharmaceuticals Llc | Trans carotenoides, su sintesis, formulacion y usos. |
CA2609549A1 (en) * | 2005-05-25 | 2006-11-30 | Sirtris Pharmaceuticals, Inc. | Treatment of eye disorders with sirtuin modulators |
WO2006127945A1 (en) | 2005-05-26 | 2006-11-30 | Neuron Systems | Compositions and methods of treating retinal disease |
WO2010148352A1 (en) * | 2009-06-19 | 2010-12-23 | Altos Vision Limited | Time-release and micro-dose formulations for topical application of estrogen and estrogen analogs or other estrogen receptor modulators in the treatment of dry eye syndrome, and methods of preparation and application |
EP2445339B1 (en) | 2009-06-22 | 2019-08-07 | Diffusion Pharmaceuticals LLC | Diffusion enhancing compound and its use with a thrombolytic |
WO2011072141A1 (en) * | 2009-12-11 | 2011-06-16 | Neuron Systems, Inc. | Compositions and methods for the treatment of macular degeneration |
EP2575487B1 (en) | 2010-06-02 | 2017-10-18 | Diffusion Pharmaceuticals Llc | Oral formulations of bipolar trans carotenoids |
CA2896032A1 (en) | 2012-12-20 | 2014-06-26 | Aldeyra Therapeutics, Inc. | Peri-carbinols |
SG11201505587YA (en) | 2013-01-23 | 2015-08-28 | Aldeyra Therapeutics Inc | Toxic aldehyde related diseases and treatment |
EP2948436A4 (en) | 2013-01-25 | 2016-07-13 | Aldeyra Therapeutics Inc | NOVEL CASES IN THE TREATMENT OF MACULAR GENERATION |
CA2996183A1 (en) | 2015-08-21 | 2017-03-02 | Aldeyra Therapeutics, Inc. | Deuterated compounds and uses thereof |
US10426790B2 (en) | 2016-02-28 | 2019-10-01 | Aldeyra Therapeutics, Inc. | Treatment of allergic eye conditions with cyclodextrins |
JP7032320B2 (ja) | 2016-03-24 | 2022-03-08 | ディフュージョン・ファーマシューティカルズ・エルエルシー | 癌を処置するための、化学療法及び放射線療法を伴う二極性トランスカロテノイドの使用 |
CA3022665A1 (en) | 2016-05-09 | 2017-11-16 | Aldeyra Therapeutics, Inc. | Combination treatment of ocular inflammatory disorders and diseases |
WO2018170476A1 (en) | 2017-03-16 | 2018-09-20 | Aldeyra Therapeutics, Inc. | Polymorphic compounds and uses thereof |
JP6923917B2 (ja) * | 2017-09-21 | 2021-08-25 | 国立大学法人福井大学 | 白内障の予防剤および治療剤、ならびに、これらを製造するためのhif経路阻害剤の使用 |
CN111356451A (zh) | 2017-10-10 | 2020-06-30 | 奥尔德拉医疗公司 | 炎性病症的治疗 |
EP3833660A4 (en) | 2018-08-06 | 2022-05-11 | Aldeyra Therapeutics, Inc. | POLYMORPHIC COMPOUNDS AND THEIR USES |
JP2022502499A (ja) | 2018-09-25 | 2022-01-11 | アルデイラ セラピューティクス, インコーポレイテッド | ドライアイ疾患を処置するための製剤 |
US11786518B2 (en) | 2019-03-26 | 2023-10-17 | Aldeyra Therapeutics, Inc. | Ophthalmic formulations and uses thereof |
WO2022255282A1 (ja) * | 2021-05-31 | 2022-12-08 | 国立大学法人大阪大学 | 動体視力向上用組成物 |
CN115105512A (zh) * | 2022-08-29 | 2022-09-27 | 中山大学中山眼科中心 | 脱氢表雄酮在制备预防、治疗眼部近视的药物中的用途及其剂型和制备方法 |
Family Cites Families (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4383992A (en) * | 1982-02-08 | 1983-05-17 | Lipari John M | Water-soluble steroid compounds |
SE8305864D0 (sv) * | 1983-10-25 | 1983-10-25 | L E Medical | Ogondroppar |
US4617299A (en) * | 1983-12-19 | 1986-10-14 | Knepper Paul A | Method for the prevention of ocular hypertension, treatment of glaucoma and treatment of ocular hypertension |
US4877774A (en) * | 1987-09-09 | 1989-10-31 | The United States Of America As Represented By The Department Of Health And Human Services | Administration of steroid hormones |
US5002935A (en) * | 1987-12-30 | 1991-03-26 | University Of Florida | Improvements in redox systems for brain-targeted drug delivery |
IE62095B1 (en) * | 1988-03-29 | 1994-12-14 | Univ Florida | Pharmaceutical formulations for parenteral use |
US5376645A (en) * | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
KR960002739B1 (ko) * | 1990-08-31 | 1996-02-26 | 데루오 니시다 | 각막 장해 치료제 |
DK0593520T3 (da) * | 1991-06-18 | 2000-04-03 | Theramex | Forbindelser med indhold af steroider og deres anvendelse til behandling af glaucom |
JP2531558B2 (ja) * | 1991-08-17 | 1996-09-04 | ルブキン、バージニア | ドライアイ症処置用の性ステロイド膏薬、同薬の調製法および適用法 |
DK0614463T3 (da) * | 1991-11-22 | 2003-03-31 | Alcon Lab Inc | Angiostatiske steroider |
US6107289A (en) * | 1992-04-21 | 2000-08-22 | The Schepens Eye Research Institute, Inc. | Ocular therapy in keratoconjunctivitis sicca using topically applied androgens or TGF-β |
EP0674528A4 (en) * | 1992-12-02 | 1996-06-26 | Insite Vision Inc | DRUG DELIVERY SYSTEM BASED ON CYCLODEXTRIN AND A POLYMER. |
US5494901A (en) * | 1993-01-05 | 1996-02-27 | Javitt; Jonathan C. | Topical compositions for the eye comprising a β-cyclodextrin derivative and a therapeutic agent |
US6142989A (en) * | 1993-05-03 | 2000-11-07 | O'donnell, Jr.; Francis E. | Apparatus and method for customized laser correction of refractive error |
US5556395A (en) * | 1993-05-07 | 1996-09-17 | Visx Incorporated | Method and system for laser treatment of refractive error using an offset image of a rotatable mask |
ZA949715B (en) * | 1993-12-14 | 1996-06-06 | Lilly Co Eli | Aqueous solution inclusion complexes of benzothiophene compounds with water soluble cyclodextrins and pharmaceutical formulations and methods thereof |
US5521168A (en) * | 1994-10-13 | 1996-05-28 | Alcon Laboratories, Inc. | Estrogen metabolites for lowering intraocular pressure |
EP0840612A1 (en) * | 1995-07-24 | 1998-05-13 | Trustees Of Boston University | Inhibition of nmda receptor activity by pregnenolone sulfate derivatives |
DE69707509D1 (de) * | 1996-07-12 | 2001-11-22 | Novo Nordisk As | 2-phenyl-3-azoylbenzothiophene zur minderung des intraokularen drucks |
DE69731302T3 (de) * | 1996-07-22 | 2011-01-20 | Renovo Ltd. | Verwendung von substanzen, die die östrogen wirkung fördern, zur behandlung von wunden |
AUPO427196A0 (en) * | 1996-12-19 | 1997-01-23 | University Of Sydney, The | A method for preventing or controlling cataract |
IL138033A0 (en) * | 1998-03-12 | 2001-10-31 | Genentech Inc | Method of preventing the death of retinal neurons and treating ocular diseases |
EP1142585A4 (en) * | 1999-01-12 | 2005-08-03 | Santen Pharmaceutical Co Ltd | DRUGS AGAINST CORNEAL DISORDERS |
US20010041745A1 (en) * | 1999-04-08 | 2001-11-15 | Bryant Henry Uhlman | Methods for increasing levels of acetylcholine |
TR200200406T2 (tr) * | 1999-06-11 | 2002-06-21 | Watson Pharmaceuticals, Inc. | Kadınlara oral olmayan yollarla androjenik steroidlerin uygulanması |
AU1735001A (en) * | 1999-12-10 | 2001-06-18 | Senju Pharmaceutical Co., Ltd. | Cyclodextrin-containing pharmaceutical composition |
EP1177787A3 (en) * | 2000-07-28 | 2003-09-10 | Pfizer Products Inc. | Use of an estrogen agonist/antagonist for treating cataracts |
US6605640B2 (en) * | 2001-01-31 | 2003-08-12 | Gerard M. Nolan | Method of treating certain eye diseases |
US20020132802A1 (en) | 2000-11-17 | 2002-09-19 | Washington Univeristy | Cytoprotective polycyclic compounds |
WO2002078680A1 (de) * | 2001-02-13 | 2002-10-10 | Dr. Gerhard Mann Chem.-Pharm. Fabrik Gmbh | Gaba-rezeptor-modulatoren zur behandlung neurodegenerativer erkrankungen des auges |
TWI320712B (en) * | 2001-09-05 | 2010-02-21 | Alcon Inc | The use of non-feminizing estrogens as retinoprotective agents for the treatment of glaucoma |
AU2004229291A1 (en) * | 2003-04-18 | 2004-10-28 | Advanced Medicine Research Institute | Remedies for diseases to be applied to eye |
-
2004
- 2004-04-16 AU AU2004229291A patent/AU2004229291A1/en not_active Abandoned
- 2004-04-16 EP EP04727990A patent/EP1621199B8/en not_active Expired - Lifetime
- 2004-04-16 EP EP10182409A patent/EP2289488A3/en not_active Withdrawn
- 2004-04-16 EP EP10177962A patent/EP2292239A3/en not_active Withdrawn
- 2004-04-16 AT AT04727990T patent/ATE488240T1/de not_active IP Right Cessation
- 2004-04-16 DE DE602004030103T patent/DE602004030103D1/de not_active Expired - Lifetime
- 2004-04-16 EP EP10182380A patent/EP2305308A1/en not_active Withdrawn
- 2004-04-16 CA CA002527175A patent/CA2527175A1/en not_active Abandoned
- 2004-04-16 EP EP10182452A patent/EP2301549A1/en not_active Withdrawn
- 2004-04-16 WO PCT/JP2004/005479 patent/WO2004091630A1/ja active Application Filing
- 2004-04-16 EP EP10178007A patent/EP2311465A1/en not_active Withdrawn
- 2004-04-16 JP JP2005505476A patent/JP4564920B2/ja not_active Expired - Fee Related
-
2010
- 2010-04-23 JP JP2010099820A patent/JP2010184927A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
CA2527175A1 (en) | 2004-10-28 |
ATE488240T1 (de) | 2010-12-15 |
AU2004229291A1 (en) | 2004-10-28 |
EP2311465A1 (en) | 2011-04-20 |
EP1621199B1 (en) | 2010-11-17 |
EP1621199A1 (en) | 2006-02-01 |
EP2301549A1 (en) | 2011-03-30 |
EP1621199A4 (en) | 2006-09-27 |
EP2305308A1 (en) | 2011-04-06 |
WO2004091630A1 (ja) | 2004-10-28 |
JP4564920B2 (ja) | 2010-10-20 |
DE602004030103D1 (de) | 2010-12-30 |
JP2010184927A (ja) | 2010-08-26 |
JPWO2004091630A1 (ja) | 2006-08-17 |
EP2289488A3 (en) | 2011-03-30 |
EP2292239A3 (en) | 2011-03-30 |
EP2289488A2 (en) | 2011-03-02 |
EP1621199B8 (en) | 2011-01-19 |
EP2292239A2 (en) | 2011-03-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2004091630A8 (ja) | 眼に適用する疾患治療剤 | |
WO2006060618A3 (en) | Topical nepafenac formulations | |
WO2009032773A3 (en) | Compositions and methods for treating demodex infestations | |
WO2006015259A3 (en) | Compounds and compositions as modulators of steroid hormone nuclear receptors | |
WO2012015810A3 (en) | Pharmaceutical compositions containing pemetrexed having extended storage stability | |
WO2007044693A3 (en) | Multi-functional ionic liquid compositions | |
AR047928A1 (es) | Derivados de tetrahidropiridoindol | |
MY147994A (en) | Azabiphenylaminobenzoic acid derivatives as dhodh inhibitors | |
IL176416A (en) | History of Nitroxy prostaglandin, pharmaceutical preparations containing them, and their use in the preparation of the drug for the treatment of glaucoma or intraocular pressure | |
WO2007092065A3 (en) | Compounds and compositions as lxr modulators | |
DOP2013000245A (es) | Preparacion de gadobutrol de alta pureza | |
WO2011014850A3 (en) | Topical eutectic-based formulations | |
IL179012A (en) | A drug containing cetirizine for the treatment of nasal inflammation, a process for its preparation and use | |
BR112015021470A2 (pt) | conjugado de polímero para administração de um agente bioativo | |
WO2014096985A3 (en) | A stable aqueous composition comprising human insulin or an analogue or derivative thereof | |
WO2007016388A3 (en) | Liquid formulations for controlled delivery of benzisoxazole derivatives | |
WO2005077122A3 (en) | Compounds and compositions as lxr modulators | |
WO2009071689A3 (de) | 5-halogen-substituierte oxindol-derivate und ihre verwendung zur behandlung von vasopressin-abhängigen erkrankungen | |
WO2009071690A3 (de) | 5,6-disubstituierte oxindol-derivate und ihre verwendung zur behandlung von vasopressin-abhängigen erkrankungen | |
WO2010021607A3 (en) | Pharmaceutical formulation | |
IL192206A0 (en) | Topical mecamylamine formulations for ocular administration and uses thereof | |
WO2008089093A3 (en) | Efficient processes for preparing steroids and vitamin d derivatives with the unnatural configuration at c20 (20 alpha-methyl) from pregnenolone | |
ES2613698T3 (es) | Combinación, kit y método de reducción de la presión intraocular | |
WO2016130800A3 (en) | Pharmaceutical compositions comprising perillyl alcohol derivatives | |
WO2005077124A3 (en) | Compounds and compositions as lxr modulators |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
DPEN | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2005505476 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11252013 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004229291 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004727990 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 5311/DELNP/2005 Country of ref document: IN |
|
CFP | Corrected version of a pamphlet front page | ||
CR1 | Correction of entry in section i |
Free format text: IN PCT GAZETTE 44/2004 UNDER (30) REPLACE "2004-004709" BY "PCT/JP2004/0004709" |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2527175 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2004229291 Country of ref document: AU Date of ref document: 20040416 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2004229291 Country of ref document: AU |
|
WWP | Wipo information: published in national office |
Ref document number: 2004727990 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 11252013 Country of ref document: US |